全球小分子 CDMO 的增长机会

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

出版日期: 2023年07月11日 | 出版商:

Frost & Sullivan | 英文 86 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

通过 Lighthoring 和标靶治疗创造未来增长

CDMO（合同开发和製造组织）是外包药物开发和製造服务的第三方供应商。在小分子药物製造领域，CDMO提供专业的开发和製造服务，现已成为製药行业价值链不可或缺的一部分。

慢性病患病率的不断上升增加了对创新小分子药物的需求。製药行业专注于开发新颖、更有效的靶向疗法，导致产品线不断增长，对创新药物输送方法的需求也不断增长。与此同时，中小型製药公司负责其研发管线中70%以上的药物，但往往缺乏将其临床管线推向市场的专业知识。

Frost & Sullivan 预计，由于对小分子口服固体剂型、标靶药物给药技术、强效和高活性药物以及其他復杂分子的需求不断增加，预测期内将出现持续增长。能够提供技术领先、灵活性、模块化製造专业知识、端到端能力和能力以及创新药物输送技术的 CDMO 将成为首选合作伙伴。为了推动增长，CDMO 将继续优先考虑製造流程各个方面的创新、协作、扩张、自动化和优化。

本报告分析了全球小分子 CDMO 市场。分析期为2021-2028年，其中2022年为基准年，2023-2028年为预测期。根据产品类型，大致分为原料药（API）/药品製造和成品药（FDF）/药品製造。此外，API分为创新药和仿製药，FDF分为口服剂型、半固体/液体剂型和注射剂型。

最重要的是，该报告根据小分子 CDMO 市场不断变化的需求和创新、标靶治疗、高活性 API 和復杂药物的出现，强调了各种规模的进入者的商机。

调查亮点

按细分市场和地区分類的盈利预测（北美、欧洲、亚太地区、世界其他地区）
主要进入者的市场份额、市场整合和业务扩张努力、服务产品和业务模式演变
影响 CDMO 选择的因素
CDMO 专注于可持续性和灵活的製造专业知识

分析范围
按产品类型细分
按服务类型细分
主要竞争
成长指数
增长促进因素
生长抑制因素
预测框架：市场规模
调查方法
预测假设
收入预测
收入预测分析
按地区分類的收入预测
按地区分類的收入预测分析
按产品类型分類的收入预测
按产品类型分類的收入预测分析
按服务类型分類的收入份额预测
按服务类型分類的收入份额预测分析
竞争环境
收入份额
收入份额分析

成长环境

小分子药物与生物製剂的审批比较
小分子市场展望：主要治疗领域和剂型
不断增长的管道和产品创新
构建 HPAPI 专业知识以实现精准医疗
扩展 CDMO 价值链：过渡到 CRDMO 模式
扩展 CDMO 价值链：全面的端到端产品
支持向 CRDMO 模式过渡的努力
向商业模式转型的能力演进：从项目型到综合长期模式
影响 CDMO 选择的因素
影响 CDMO 选择的因素：分析
以 ESG 为重点的倡议，成为首选合作伙伴
小分子 CDMO 行业的整合步骤
通过利用规模和扩大投资组合来努力扩张
塑造小分子 CDMO 行业的增长趋势：总结

增长机会分析：API (API)

成长指标
盈利和预测
按产品类型分類的收入预测
预测分析

增长机会分析：FDF（成品配方）

成长指数
收入预测
按产品类型分類的收入预测
预测分析：口服药物
预测分析：注射剂
预测分析：液体/半固体配方
预测分析：其他

充满增长机会的宇宙

增长机会 1：BA 增强型 OSD 配方解决方案
增长机会2：标靶治疗药物的放射性药物製造
增长机会 3：用于系列化的创新互联包装解决方案
增长机会4：差异化注射专用仿製药的能力

下一步

下一步
现在为何选择 Frost & Sullivan？
附件清单
免责声明

简介目录

Product Code: PEA0-52

Right Shoring and Targeted Therapeutics Create Future Growth

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain.

The growing incidence of chronic diseases propels the demand for innovative small-molecule medicines. The pharmaceutical industry's focus on developing novel, more efficacious, and targeted therapies has resulted in increased product pipelines and the need for innovative drug delivery methods. Simultaneously, while small and mid-sized pharma companies are responsible for over 70% of drugs in the R&D pipeline, they often lack the expertise to bring their clinical pipeline to market.

Frost & Sullivan expects sustained growth during the forecast period, driven by increasing demand for small molecules in oral solid formulations, targeted drug delivery technologies, potent and highly potent drugs, and other complex molecules. CDMOs equipped to provide technological leadership, flexibility, expertise for modular manufacturing, end-to-end capabilities and capacities, and innovative drug delivery technologies will likely emerge as the partner of choice. To drive growth, CDMOs will continue prioritizing innovation, collaboration, expansion, automation, and optimization across all aspects of the manufacturing process.

In this report, Frost & Sullivan overviews the global small-molecule CDMO market. The study period is 2021-2028, with 2022 as the base year and 2023-2028 as the forecast period. We segment the study into two main categories based on the product type: active pharmaceutical ingredients (API)/drug substance manufacturing and fixed dosage form (FDF)/drug product manufacturing. Frost & Sullivan segments API further into innovator and generic and FDF into oral, semisolid/liquid, and injectables.

Most importantly, the report highlights opportunities for participants of all sizes based on the evolving needs and innovations in the small-molecule CDMO market, the emergence of targeted therapeutics, highly potent APIs, and complex drugs.

Research Highlights

Revenue forecasts by segment and region (North America, Europe, Asia-Pacific, and the Rest of the World)
Market share of leading participants, consolidation and expansion initiatives, and developments in service offerings and business models
Factors influencing CDMO selection
CDMOs’ focus on sustainability and flexible manufacturing expertise

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Global Small Molecule CDMO Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

Scope of Analysis
Segmentation by Product Type
Segmentation by Service Type
Key Competitors
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Framework: Market Sizing
Forecast Methodology
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Share Forecast by Service Type
Revenue Share Forecast Analysis by Service Type
Competitive Environment
Revenue Share
Revenue Share Analysis

Growth Environment

Comparison Between Small Molecules and Biologics Approvals
Small Molecule Market Outlook: Main Therapy Area and Dosage Form
Growing Pipeline and Product Innovation
Building Expertise in HPAPI Enabling Precision Medicine
Expanding the CDMO Value Chain: Transition to a CRDMO Model
Expanding the CDMO Value Chain: Comprehensive End-to-end Offering
Initiatives Supporting Transition to the CRDMO Model
Capability Evolution for Transitioning the Business Model from Project-based to Integrated Long-term
Factors Influencing CDMO Selection
Factors Influencing CDMO Selection: Analysis
ESG-focused Initiatives to Become a Partner-of-Choice
Consolidation Steps in the Small Molecule CDMO Industry
Expansion Initiatives to Capitalize on Scale and Broadening Portfolio
Summary of Growth Trends Shaping the Small Molecule CDMO Industry

Growth Opportunity Analysis: API

Growth Metrics
Revenue Forecast
Revenue Forecast by Product Type
Forecast Analysis

Growth Opportunity Analysis: FDF

Growth Metrics
Revenue Forecast
Revenue Forecast by Product Type
Forecast Analysis: Oral
Forecast Analysis: Injectable
Forecast Analysis: Liquids/Semisolids
Forecast Analysis: Others

Growth Opportunity Universe

Growth Opportunity 1: BA Enhancement Solutions for OSD Formulation
Growth Opportunity 2: Radiopharmaceutical Manufacturing for Targeted Therapeutics
Growth Opportunity 3: Innovative and Connected Packaging Solutions for Serialization
Growth Opportunity 4: Differentiated Capabilities for Injectable Specialty Generics